Login to Access Video or Poster Abstract: MP91-14
Sources of Funding: none

Introduction

ED is a predictive risk factor for CVD. We monitored effectiveness and safety of long-term Testosterone Therapy (TTh) in hypogonadal men with a history of CVD._x000D_ _x000D_

Methods

Two observational registry studies of 622 hypogonadal men from two urological centers: 77 men with a previous diagnosis of coronary artery disease (CAD; n=48) and/or a myocardial infarction (MI; n=40) and/or stroke (n=7) received TU for up to 8 years.

Results

Mean age was 60.65 ± 4.98 years, mean follow-up time was 7.29 ± 1.20 years. Testosterone (T) levels rose from 9.78 ± 1.56 nmol/L to trough levels (measured prior to the following injection) between 16 and 18 nmol/L. IIEF-EF (maximum score: 30) increased from 19.64 ± 6.34 to 24.49 ± 4.69 with a change from baseline of 5.37±0.36, this improvement was statistically significant for the first three years and remained statistically significant vs baseline throughout the observation time and stable compared to previous years._x000D_ Weight decreased progressively from 114.47 ± 13.41 to 90.42 ± 8.77 by 23.6 ± 0.6 kg, proportion of weight loss: 19.62 ± 5.71%. Waist circumference decreased from 111.78±8.22 to 99.24 ± 6.48 by 12.51 ±0.37 cm. The waist:height ratio improved from 0.64 ± 0.05 to 0.57 ± 0.04 (p<0.0001 for all)._x000D_ Blood pressure (BP, mmHg): Systolic BP decreased from 164.45 ± 14.4 to 132.96 ± 8.71, diastolic BP from 99.48 ± 11.37 to 76.39 ± 4.89, pulse pressure from 64.97 ± 6.48 to 56.57 ± 8.02 (p<0.0001 for all)._x000D_ Lipid pattern and glycaemic control improved significantly and sustainably. C-reactive protein (CRP) declined from 3.69 ± 4.51 to 0.25 ± 0.28 mg/dl._x000D_ In no patient was testosterone therapy discontinued or interrupted. No cardiovascular events were reported during the observation time._x000D_

Conclusions

In hypogonadal men with a history of CVD, T therapy may improve and preserve erectile function for a prolonged period of time. No cardiologic or urologic events observed during entire period of T therapy. TTh appears to be well-tolerated and safe

Funding

none